Comments Submitted to Colorado PDAB on Draft Proposed Rule Concerning the Affordability Review of Prescription Drugs

RDCC submitted comments to Board Members of the Colorado Prescription Drug Affordability Review Board (PDAP) concerning the impact a proposed rule could have on advancing research and development for new and innovative rare disease therapies. The Coalition asserted that the draft proposed rule as written could “in the long run harm more patients than it helps.”

In this letter, the RDCC strongly urges the PDAB to consider the unique circumstances of rare disease patients and therapies as it crafts its policy proposals, and cautions against punitive measures that would have an outsized impact on rare diseases. The impact of misguided policy proposals could stall future investment and development of rare disease treatments that would further disadvantage rare disease patients.

Click here to download and read the letter submitted from our Coalition to Colorado PDAP.